|
|
News Breaks | | | | November 5, 2012 | | 10:21 EDT |  | ARRY | Array BioPharma to present data at ASH meeting
Array BioPharma announced that data will be presented on two drug candidates, ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor, at the 2012 Annual Meeting of the American Society of Hematology. Array will also hold a conference call today at 4:30 p.m. ET, to review the abstracts. Early data from the ongoing combination with carfilzomib is reported in an abstract. In the ARRY-614 abstract, new formulation demonstrated improved bioavailability and inter-patient variability with in th ongoing study in low or intermediate-1 risk Myelodysplastic Syndromes, Array said. In its prior study in a similar population, the company said it observed a 38% response rate for hematologic improvement in patients receiving the highest dose of our prior formulation. At this dose, ARRY-614 demonstrated multilineage hematologic improvement in 67% of the responders, improving two or more cytopenia. Array intends to meet with the FDA to discuss the development plan to support registration. | |
|
News For ARRY From The Last 14 Days Check below for free stories on ARRY the last two weeks. |
|
|
| June 17, 2013 | | 08:01 EDT | | ARRY | Array BioPharma announces positive interim results from tiral of ARRY-520
 Subscribe for More Information | | | 07:28 EDT |  | ARRY | Cambridge Healthtech Institute to host a conference
Subscribe for More Information | | | 06:07 EDT |  | ARRY | Array BioPharma pullback a buying opportunity, says Piper Jaffray
Subscribe for More Information | |
|
|
|
|
|
|
